PSGL-1 deficiency re-wires T cell signaling to support development of stem cell like exhausted T cells that control PD-1 blockade resistant melanoma tumor growth
نویسندگان
چکیده
Abstract We previously identified that the adhesion molecule P-selectin glycoprotein ligand-1 (PSGL-1) regulates CD8 +T cell effector functions and promotes exhaustion in responses to chronic viral infection melanoma tumors. In this study, we investigated cellular molecular mechanisms by which intrinsic PSGL-1 signaling differentiation of exhausted T cells (T EX). show localizes with TCR upon co-ligation find associates Zap70 inhibitor, Sts-1. absence PSGL-1, expression Sts-1 is reduced allowing for greater activation downstream molecules Akt Erk1/2. addition, PSGL-1-deficiency empowers respond low affinity ligands. vivo, deficiency leads growth inhibition a PD-1-blockade resistant melanoma. Notably, enables retention EFF) functions, an increased representation stem cell-like SC) express TCF-1 levels TOX, are associated sustained responsiveness ICB. now concomitant repeated stimulation human EFFelicits functional exhaustion. Importantly, blockade recapitulates anti-tumor as well antiviral responses, its distinct mechanism underscores translational potential targeting Supported grants from NIH (R01 AI106895, R21 CA249353, CA216678, R03 CA252144) Melanoma Research Alliance MRA 696326, Department Defense W81XWH-20-1-0324, Sanford Burnham Prebys NCI-Designated Cancer Center Support Grant, P30 CA030199 American Society Postdoctoral Fellowship (PF-20-113-01-LIB)
منابع مشابه
Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
The programmed death (PD)-1-PD-1 ligand (PD-L) pathway, which is part of the B7-CD28 family, consists of the PD-1 receptor and its two ligands PD-L1 and PD-L2. Engagement of PD-1 by its ligands inhibits immune responses, and recent work has shown that PD-1 is highly expressed on exhausted T cells during chronic lymphocytic choriomeningitis virus (LCMV) infection in mice. Blockade of this pathwa...
متن کاملDevelopment of a Stable Cell Line, Overexpressing Human T-cell Immunoglobulin Mucin 1
Background: Recent researches have demonstrated that human T-cell immunoglobulin mucin 1 (TIM-1) glycoprotein plays important roles in regulation of autoimmune and allergic diseases, as well as in tumor immunity and response to viral infections. Therefore,targeting TIM-1 could be a potential therapeutic approach against such diseases. Objectives: In this study, we aimed to express TIM-1 protein...
متن کاملBlockade of PD-1 immunosuppression boosts CAR T-cell therapy
The presence of an immunosuppressive microenvironment can limit the full potential of adoptive T cell immunotherapy. However, specific blockade of the PD-1 immunosuppressive pathway can significantly enhance the function of gene-modified T cells expressing a chimeric antigen receptor (CAR) leading to enhanced tumor eradication.
متن کاملProducing Soluble Human Programmed Cell Death Protein-1: A Natural supporter for CD4+T cell Cytotoxicity and Tumor Cells Apoptosis
Background: Programmed cell death protein-1 (PD-1)/PD-L1 pathway is one of the immune checkpoint pathways involved in regulation of the immune responses and suppression of anti-tumor defense. PD-1/B7-H1-blocking antibodies improve immune responses such as cytotoxic activity of CD8+/CD4+T cells and also increase mortality of tumor cells; however their use is accompanied by adverse effects in pat...
متن کاملHuman CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Following immune attack, solid tumors upregulate coinhibitory ligands that bind to inhibitory receptors on T cells. This adaptive resistance compromises the efficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid tumors. Here, we investigated whether programmed death-1-mediated (PD-1-mediated) T cell exhaustion affects mesothelin-targeted CAR T cells and ex...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Immunology
سال: 2023
ISSN: ['1550-6606', '0022-1767']
DOI: https://doi.org/10.4049/jimmunol.210.supp.172.24